POS1138 SERUM URIC ACID-TO-CREATININE RATIO: A POTENTIAL MARKER FOR GOUT

Background: Serum uric acid-to-creatinine ratio (SUA/Cr) is a useful index of renal function-normalized serum acid (SUA), which reflects endogenous SUA levels more precisely than SUA. SUA/Cr relates to disease activity and prognosis several metabolic disorders, like syndrome, non-alcoholic fatty liver disease, diabetes mellitus [1]. Besides, the urine valuable for assessment gout [2]. However, no study focuses on relationship between gout. Objectives: We aimed investigate features demography, manifestations, laboratory tests, urate-lowering therapies (ULTs) in patients. Methods: This cross-sectional was performed from December 2015 February 2020. Medical records patients who were regularly undergone follow-up evaluated. Characteristics patients, included age, gender, duration gout, body mass (BMI), tophus, complications, number flares, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), recorded. Complications defined as hypertension, coronary artery diseases, diabetes, strokes, and/or diseases. Information about ULT obtained well. The Spearman correlation analysis used assess continuous variables. Mann-Whiney U test or Kruskal-Wallis employed compare differences genders, ULTs, whether had tophus complications. A P<0.05 considered statistically significant. Results: (1) Of 627 involved, 608 (96.97%) male. Their median (range) age 30.00 (51.00) years 5.00 (30.00) years, respectively. (2) negatively correlated with (r=-0.71, P<0.05). similar genders. (3) positively BMI (r=0.14, P<0.05), while coefficient flares did not reach significant (P>0.05). significantly higher complications others [5.56 (9.26) vs. 4.16 (8.34), P<0.05], but shared SUA/Cr. (4) CRP ESR associate (5) Patients combination therapy xanthine oxidase inhibitor uricosuric agent lower compared those ULTs monotherapy [3.44 (7.10) 4.53 (7.91), P<0.05]. Conclusion: some so it may be potential marker its assessment. References: [1]Medicine (Baltimore) 2020;99(17):e19959. [2]J Korean Med Sci 2020;35(13):e95. Disclosure Interests: None declared.